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Prospective multicentre cohort study of heparin-induced
thrombocytopenia in acute ischaemic stroke patients
Immune-mediated heparin-induced thrombocytopenia (HIT),
which is caused by platelet-activating IgG antibodies that
recognize platelet factor 4 bound to heparin (anti-PF4/heparin
Abs), is a relatively common side effect of heparin therapy and
presents a strong risk factor for thromboembolic events
associated with high mortality and morbidity (Warkentin,
2007a). Prospective studies in Western countries have shown
that the prevalence of HIT is 0Æ3–5% of patients treated with
unfractionated heparin (UFH), which varies depending on the
clinical settings (Warkentin et al, 1995, 2000; Kappers-Klunne
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Summary
Acute ischaemic stroke patients sometimes receive heparin for treatment and/
or prophylaxis of thromboembolic complications. This study was designed to
elucidate the incidence and clinical features of heparin-induced
thrombocytopenia (HIT) in acute stroke patients treated with heparin. We
conducted a prospective multicentre cohort study of 267 patients who were
admitted to three stroke centres within 7 d after stroke onset. We examined
clinical data until discharge and collected blood samples on days 1 and 14 of
hospitalization to test anti-platelet factor 4/heparin antibodies (anti-PF4/H
Abs) using an enzyme-linked immunosorbent assay (ELISA); platelet-
activating antibodies were identiﬁed by serotonin-release assay (SRA).
Patients with a 4Ts score ‡4 points, positive-ELISA, and positive-SRA were
diagnosed as deﬁnite HIT. Heparin was administered to 172 patients (64Æ4%:
heparin group). Anti-PF4/H Abs were detected by ELISA in 22 cases (12Æ8%)
in the heparin group. Seven patients had 4Ts ‡ 4 points. Among them, three
patients (1Æ7% overall) were also positive by both ELISA and SRA. National
Institutes of Health Stroke Scale score on admission was high (range, 16–23)
and in-hospital mortality was very high (66Æ7%) in deﬁnite HIT patients. In
this study, the incidence of deﬁnite HIT in acute ischaemic stroke patients
treated with heparin was 1Æ7% (95% conﬁdence interval: 0Æ4–5Æ0). The
clinical severity and outcome of deﬁnite HIT were unfavourable.
Keywords: acute stroke care, anticoagulation, heparin, platelet, thrombocy-
topenia.
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mately one-third to one-half of HIT patients (Warkentin,
2007a). On the other hand, some studies of UFH therapy for
acute stroke reported no cases of HIT (Toth & Voll, 2002;
Camerlingo et al, 2005). To elucidate the prevalence of HIT in
acute ischaemic stroke patients who were treated with heparin,
we organized a prospective multicentre cohort study that
included systematic collection of blood for detection of the
antibodies that cause HIT.
Some clinical guidelines do not recommend prescribing
heparin in acute ischaemic stroke, and others recommend it
mainly for the prevention of deep vein thrombosis (DVT) and
pulmonary embolism (PE) (Albers et al, 2004; Cardiovascular
Disease Educational and Research Trust, 2006; Adams et al,
2007). At the participating stroke centres in our study, in
addition to the prevention of DVT and PE, UFH is given
during the acute phase of ischaemic stroke to the following:
patients with emboligenic heart disease or superimposed
thrombi on the carotid plaque to prevent embolic complica-
tions; patients with particular stroke aetiologies, including
cerebral arterial dissection and vasculitis; and patients with
embolic stroke of unknown origin until the presence of heart
disease is excluded by the results of prolonged electrocardio-
graphy and transesophageal echocardiography (Caplan, 2003).
In a previous study of 137 stroke patients who were treated
with UFH, 21 patients (15Æ3%) developed thrombocytopenia
(‡40% fall in platelet counts) during or after heparin therapy,
and ﬁve of these 21 patients had an additional ischaemic stroke
(Ramirez-Lassepas et al, 1984). A recent study of 200 neuro-
logical patients treated with UFH for at least 5 d, including 102
patients with cerebrovascular disorders, demonstrated that 41
patients (20Æ5%) had anti-PF4/heparin Abs and 5 (2Æ5%)
developed HIT, when the serological diagnosis was made from
the presence of antibodies detected by an enzyme-linked
immunosorbent assay (ELISA) (Harbrecht et al, 2004).
Only a few studies have investigated the prevalence of HIT in
acute stroke patients receiving UFH, especially in the Asian
population (Kawano et al, 2008). In our previous retrospective
report of acute ischaemic stroke patients who were treated with
UFH,0Æ5%ofthepatientsdevelopedHITdiagnosedbyboththe
clinical scoring systems and the serological assays, including
14C-serotonin release assay (SRA) (Kawano et al, 2008). How-
ever,ourretrospectivestudyassessingtheprevalenceofHITwas
limitedbythefactthatwasthatantibodieswerenotassayedinall
patients. This limitation may cause an under diagnosis of HIT.
Thus, we performed this prospective multicentre cohort
study in 267 patients to determine a more accurate incidence
of HIT in patients with acute ischaemic stroke and to elucidate
the clinical features of HIT.
Methods
Study design
A prospective multicentre cohort study.
Subjects and settings
This study was conducted in three Japanese stroke centres at the
then National Cardiovascular Centre (currently the National
Cerebral and Cardiovascular Centre, Osaka), Research Institute
for Brain and Blood Vessels Akita (Akita), and Kumamoto
University (Kumamoto). Between October 2006 and May 2007,
all consecutive patients who met the following criteria were
enrolled. Eligible patients were 20 years of age or older and
admitted within 7 d after the onset of acute ischaemic stroke,
including cerebral infarction and transient ischaemic attack.
Patients were excluded for any of the following: (i) active
infectious endocarditis, (ii) urgent neurosurgery or cardiovas-
cularsurgerywouldberequired,(iii)chronicthrombocytopenia
(deﬁned as a platelet count <100 · 10
9/l for more than 30 d),
(iv) haematopoietic malignancy and (v) an ongoing need for an
anticancer-drug treatment. The study was approved by the
research ethics committee of each centre. Heparin therapy was
provided to a number of patients depending on the physician’s
decision (mainly considering the type of stroke and/or the
patient’s clinical status as described in the Introduction.)
Evaluation
The following patient characteristics were obtained: age, sex,
height, body weight, body-mass index, modiﬁed Rankin Scale
(mRS) score (van Swieten et al, 1988) before stroke onset,
vascular risk factors (hypertension, diabetes mellitus, dyslip-
idaemia, current and past smoking habits, drinking habit,
including occasional drinking), past history (autoimmune
disease, haemodialysis, renal dysfunction, angina, myocardial
infarction, cerebral infarction, transient ischaemic attack,
pulmonary thromboembolism, extremity gangrene, amputa-
tion of an extremity, angiography, heparin exposure, surgical
procedure and HIT), platelet counts, antiplatelet/anticoagulant
drug use and blood transfusions. The timing and period of
heparin administration (including heparin ﬂushes), changes in
platelet count, and alternative anticoagulant therapy for HIT
(if given) were also examined. Other risk factors for stroke,
such as emboligenic heart diseases including atrial ﬁbrillation,
were assessed based on the criteria from the Trial of Org 10172
in Acute Stroke Treatment (TOAST) study (Adams et al,
1993). Based on the neurological, radiological, cardiological
and haematological proﬁles, the stroke subtype was deter-
mined according to the TOAST subtype classiﬁcation system
by a consensus of stroke neurologists. The neurological severity
of each patient was assessed by an experienced stroke
neurologist according to the National Institutes of Health
Stroke Scale (NIHSS) score (Lyden et al, 1994) on admission
and discharge, and at 3 months after onset. Patient global
outcome was also assessed with mRS (van Swieten et al, 1988).
Clinical evaluation. The clinical probability of HIT was
assessed using the 4Ts scoring system (Warkentin & Heddle,
2003), which is composed of four clinical features that are
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timing of platelet count fall (in relation to heparin therapy);
thrombosis or other sequelae; and presence of other
explanations for thrombocytopenia. The case reports of the
patients, ﬁlled out by their physicians, were assessed
independently in a blinded fashion by the external Data
Assessment Committee, which consisted of two stroke
neurologists, according to the 4Ts scoring system after the
patient follow-up was completed. If the judgment was not
concordant between the two stroke neurologists, they
discussed the cases to reach a ﬁnal consensus and decision.
Based on the 4Ts score, the estimated pretest probabilities of
HIT were categorized into three groups: low (0–3),
intermediate (4–5) and high (6–8) scores. We diagnosed the
patients with an intermediate or a high score as ‘potential HIT’
and those with a low score as ‘clinical non-HIT’. These
objective assessments for the clinical probability of HIT were
done after the patient follow-up was completed as described
above, so that no results inﬂuenced clinical management.
Therefore, some patients were ultimately diagnosed as HIT
even though the physicians in charge did not suspect HIT as
described in details in the Results section.
Serological evaluation. Blood samples were collected from all
patients on the ﬁrst (to the third) and 14th (±4) hospital days
to be tested for anti-PF4/heparin Abs using ELISA
(Asserachrom HPIA; Diagnostica Stago, Asnieres, France).
The assays were performed in a blinded fashion after patient
follow-up was completed. ELISA was performed according to
the manufacturer’s instructions. The titres of the samples were
expressed as values of optical density (OD). The result was
considered positive when the titre was greater than the cut-off
value, which was determined using the reference control for
each kit. To conﬁrm the diagnosis of HIT, SRA was measured
for all patients with a positive ELISA and/or ‡4 points in the
4Ts scoring system (n = 29). In addition, samples from 39
patients selected randomly from among all the patients were
tested by SRA as a control. Samples were measured as
described elsewhere at the Platelet Immunology Laboratory,
McMaster University (Hamilton, ON, Canada) blinded to all
clinical, platelet count and serological data (Warkentin et al,
1992). Any sample that produced ‡10% mean serotonin
release with <10% release in the presence of high heparin (at a
ﬁnal concentration of 100 u/ml) and the anti-FccRIIa
monoclonal antibody (IV.3) was considered SRA-positive.
Diagnosis
Based on the results of both the 4Ts clinical score and the
serological assays, patients were categorized into four groups as
follows: (i) deﬁnite HIT (4Ts score ‡4 points with positive
results in both ELISA and SRA), (ii) possible HIT (4Ts score
‡4 points with positive result in either ELISA or SRA) and (iii)
clinically suspected HIT (4Ts score ‡4 points with negative
results in both ELISA and SRA), seropositive status (4Ts score
<4 points with positive in both ELISA and SRA). The
remaining patients were categorized as HIT unlikely.
Statistical analysis
The variables between the groups of patients treated with and
without heparin were compared using Fisher’s exact test and
the Wilcoxon test. For NIHSS, the change, NIHSS score at
discharge minus that at admission, was also determined.
Statistical analyses were performed using sas software version
9.1 (SAS Institute Inc, Cary, NC, USA).
Results
Patient characteristics
A total of 267 patients (mean age 71Æ7 years; 66Æ2% men),
who were admitted to three stroke centres within 7 d after
stroke onset during a 6-month period, were enrolled.
Intravenous UFH was administered to 172 patients (64Æ4%:
heparin group) (Fig 1). Male gender, atrial ﬁbrillation,
previous ischaemic heart disease, history of surgery using
UFH, and history of intra-arterial catheter procedures were
signiﬁcantly more common in patients treated with than
without UFH (Table IA). In regard to stroke subtype, large
artery atherosclerosis and cardioembolism were more frequent
in patients treated with UFH, and small vessel occlusion was
more frequent in those without UFH treatment. There was no
signiﬁcant difference in the history of antiplatelet drug use
before admission between the patients treated with (66 cases,
38Æ4%) and without UFH (32 cases, 33Æ7%) (P =0 Æ508)
(Table IA). Both the NIHSS score at discharge (median, 2 vs.
1, P =0 Æ020) and mRS at 3 months after stroke onset
(median, 2 vs. 1, P <0 Æ001) were higher in patients treated
with UFH (Table IB).
The incidence of HIT
Anti-PF4/heparin Abs were detected at any time point in 22
patients (12Æ8%) in the heparin group and in 3 (3Æ2%) of 95
patients who did not receive intravenous UFH respectively
(Fig 1), and the difference was signiﬁcant (P =0 Æ008). Seven
patients (4Æ1%) were diagnosed as having potential HIT
according to the 4Ts score (‡4 points). All seven patients had
intermediate scores. Among them, three showed positive
results in both ELISA and SRA, to give an incidence of
deﬁnite HIT of 1Æ7% [95% conﬁdence interval (CI): 0Æ4–5Æ0].
Possible HIT, clinically suspected HIT, and seropositive status
were 0%, 2Æ3% (n = 4), and 2Æ3% (n = 4), respectively (Fig 1).
Of the 95 patients with a positive ELISA who did not receive
heparin within 3 months before admission and/or during
hospitalization, three were SRA-negative. The OD values of
anti-PF4/heparin Abs detected by ELISA seemed a little higher
in deﬁnite HIT patients than the seropositive status group,
although statistical analysis was not performed because of the
H. Kawano et al
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correlate with the mean percentage release in SRA (Fig 2).
However, the proportion of samples with positive-SRA to
those with negative-SRA was greater in the samples with ‡1Æ5
OD value in ELISA as compared to those with <1Æ5 OD value.
The prevalence of positive-ELISA was not signiﬁcantly differ-
ent between patients who received UFH for ﬁve or more days
(15Æ9%) and for <5 d (11Æ4%).
Clinical course and the treatment of deﬁnite HIT patients
Only one (Case 3) of three deﬁnite HIT patients was suspected
of having HIT by the treating physician. This patient had
atrial ﬁbrillation and an infarct in the right anterior and
middle cerebral arteries. The admission NIHSS score was 17
(Table II). The patient’s platelet count decreased from 156 to
99 · 10
9/l (approximately a 37% fall) in the typical HIT
window (5–10 d) and recovered to 227 · 10
9/l soon after
stopping heparin administration on day 7 due to the suspi-
cion of HIT. The patient had a further fall in platelet count,
from 227 to 99 · 10
9/l (approximately a 56% fall), after
day 10 with a high OD value (2Æ086) in ELISA and a weak
positive SRA (11% release) (Table II). The patient died due to
deterioration from an underlying stroke. The very weak SRA,
which was performed during the second platelet count fall,
argues somewhat against this patient having HIT. However,
HIT antibodies sometimes become weaker very quickly
(Warkentin & Kelton, 2001; Greinacher et al, 2009), and so
it is possible that the SRA would have been stronger during
the ﬁrst platelet count fall.
The other two patients (Cases 1 and 2) that ultimately met
the criteria for deﬁnite HIT in this study were not suspected of
having HIT by their physicians. One patient (Case 1)
experienced a stroke of other determined aetiology due to
arterial dissection in the intracranial left vertebral artery. The
admission NIHSS score was 23 (Table II). The patient had
bilateral cerebellar and brain stem infarcts. UFH was admin-
istrated for 7 d, and UFH ﬂushes for intravascular catheter
were continued for an additional 4 d. The patient showed a
52Æ0% decrease in platelet count, from 331 to 107 · 10
9/l, that
began on day 5 of heparin with relatively high values in SRA
(63Æ9% release) and ELISA (2Æ271 OD value) (Table II). Death
occurred from stroke on day 11. The other patient (Case 2)
with a previous history of recent transient ischaemic attacks
had a cardioembolic stroke due to atrial ﬁbrillation 9 d after
urgent hemiarch replacement due to aortic dissection. The
admission NIHSS score was 16. The patient’s platelet count
declined from 436 to 286 · 10
9/l (a drop of approximately
34%) during the typical HIT window of days 5–10 with
relatively high values in SRA (51Æ6% release) and ELISA (1Æ725
OD value); although the platelet count evolution may be
explained by a platelet count proﬁle of post-cardiovascular
surgery with cardiopulmonary bypass overshooting around
postoperative day 14 and returning gradually to the baseline
(Table II). The patient was dependent at discharge and at
3-month follow-up.
Fig 1. Flow chart for diagnosis of heparin-induced thrombocytopenia. HIT, heparin-induced thrombocytopenia; UFH, unfractionated heparin;
ELISA, enzyme-linked immunosorbent assay; SRA, serotonin-release assay.
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ª 2011 Blackwell Publishing Ltd, British Journal of Haematology, 154, 378–386 381Table I. (A) Demographic data of patients treated or not with unfractionated heparin (UFH) and (B) clinical data of patients treated or not with
UFH.
With UFH
(n = 172; 64Æ4%)
Without UFH
(n = 95; 35Æ6%) P-value
(A)
Age (years), median (range) 71 (23–98) 73 (42–93) 0Æ515
Male gender (%) 122 (70Æ9) 53 (55Æ8) 0Æ015
Weight (kg) 60Æ1±1 2 Æ25 9 Æ4±1 1 Æ60 Æ673
BMI (kg/m
2)2 3 Æ3±3 Æ82 3 Æ4±3 Æ70 Æ936
HTN (%) 133 (77Æ3) 74 (77Æ9) 1Æ000
DM (%) 55 (32Æ0) 30 (31Æ6) 1Æ000
CRF (%) 17 (9Æ9) 5 (5Æ3) 0Æ247
HD (%) 3 (1Æ7) 0 (0) 0Æ555
Atrial ﬁbrillation (%) 59 (34Æ3) 11 (11Æ6) <0Æ001
Smoking (%) 78 (45Æ3) 37 (38Æ9) 0Æ303
Drinking (‡2 cups) (%) 49 (28Æ5) 21 (22Æ1) 0Æ249
Previous IHD (%) 33 (19Æ2) 5 (5Æ3) 0Æ002
Previous CVD (%) 51 (29Æ7) 28 (29Æ5) 1Æ000
Previous PTE (%) 0 0 –
Previous DVT (%) 4 (2Æ3) 1 (1Æ1) 0Æ658
History of heparin use within 3 months (%) 6 (3Æ5) 0 (0) 0Æ180
History of surgery using heparin 33 (19Æ2) 3 (3Æ2) <0Æ001
History of intra-arterial catheter procedure (%) 43 (25Æ0) 8 (8Æ4) <0Æ001
History of warfarin use (%) 18 (10Æ5) 5 (5Æ3) 0Æ176
History of antiplatelet agency use (%) 66 (38Æ4) 32 (33Æ7) 0Æ508
Stroke subtype
TIA (%) 9 (5Æ2) 20 (21Æ1) <0Æ001
Stroke (%) 163 (94Æ8) 75 (78Æ9)
LAA (%) 38 (23Æ3) 5 (6Æ7)
CE (%) 64 (39Æ3) 5 (6Æ7) <0Æ001
SV (%) 26 (16Æ0) 48 (64Æ0)
OT + UD (%) 35 (21Æ5) 17 (22Æ7)
Platelet count (·10
9/l) 222 (103–583) 230 (119–483) 0Æ670
NIHSS score on admission, median (range) 5 (0–32) 3 (0–20) <0Æ001
(B)
Treatment during the hospital stay
Warfarin use (%) 70 (40Æ7) 9 (9Æ5) <0Æ001
Antiplatelet agency use (%) 105 (61Æ0) 84 (88Æ4) <0Æ001
Cessation of heparin (%) 142 (82Æ6) 0 <0Æ001
Alternative anticoagulation (%) 67 (39Æ0) 37 (38Æ9) 1Æ000
Intra-arterial catheter procedure during
the hospital stay (%)
70 (40Æ7) 0 (0) <0Æ001
Surgery with heparin use during the hospital stay 7 (4Æ1) 0 (0) 0Æ053
Thromboembolic vents or death 25 (14Æ5) 4 (4Æ2) 0Æ012
Recurrence of ischaemic stroke 12 (7Æ0) 2 (2Æ1)
Thromboembolic events during catheter 4 (2Æ3) 0
Other thromboembolism 7 (4Æ1) 2 (2Æ1)
React of heparin infusion 1 (0Æ6) 0
Death 5 (2Æ9) 0
NIHSS score at discharge, median (range) 2 (0–42) 1 (0–20) –
NIHSS change, discharge-admission (range) )2( )21 to 19) )1( )8t o9 ) 0 Æ020
mRS at discharge, mean (median) 2 (0–6) 1 (0–5) 0Æ002
mRS at 3 months, median (range) 2 (0–6) 1 (0–5) <0Æ001
BMI, body mass index; HTN, hypertension; DM, diabetes mellitus; CRF, chronic renal failure; HD, haemodyalysis; IHD, ischaemic heart disease;
CVD, cerebrovascular disease; PTE, pulmonary thromboembolism; DVT, deep vein thrombosis; TIA, transient ischaemic attack; LAA, large artery
atherosclerosis; CE, cardioembolism; SV, small vessel occlusion; OT, stroke with alternative aetiology; UD, stroke of undetermined aetiology; UFH,
unfractionated heparin; NIHSS, National Institutes of Health Stroke Scale; mRS, modiﬁed Rankin scale.
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or delayed onset HIT. None of the patients classiﬁed as deﬁnite
HIT received treatment with alternative anticoagulants, such as
thrombin inhibitors, nor did the patients develop additional
thromboembolic events.
Discussion
HIT should be recognized as a clinicopathological syndrome
because none of the currently available HIT diagnostic tools
have sufﬁcient sensitivity and speciﬁcity to be used as the
primary or only tool to diagnose HIT. Thus, both clinical and
serological diagnoses are crucial. In this prospective study,
clinical probability was assessed using the 4Ts scoring system,
which is a popular method, by two independent stroke
neurologists who were blinded from the results of serological
assays. As a result, 4Æ1% of the acute stroke patients treated
with heparin were suspected clinically of having HIT with
‡4 points in the 4Ts scoring system. Among them, 1Æ7% (95%
CI: 0Æ4–5Æ0) had platelet activating antibodies against the
complexes of PF4 and heparin detected by ELISA and SRA,
supporting the diagnosis of deﬁnite HIT. All of these deﬁnite
HIT patients had intermediate scores in the 4Ts as well as four
clinically suspected HIT cases, as shown in Table II. Thus, it
was very difﬁcult to distinguish HIT patients from non-HIT
patients through clinical information alone. This may possible
explain why only one among three deﬁnite HIT cases was
suspected of having HIT by the treating physicians.
Our results were similar to those reported in other studies of
patients with ischaemic stroke (Ramirez-Lassepas et al, 1984;
Harbrecht et al, 2004) and the frequency of deﬁnite HIT was
less than in surgical patients (Kappers-Klunne et al, 1997;
Warkentin, 2007b). For two of the three deﬁnite HIT patients
reported here, one had a possible alternative aetiology that
could explain her platelet count fall (Case 2) and the other had
a weak positive-SRA (Case 1) as described in detail in the
Result section. Thus, we cannot exclude the possibility that
these two patients might not have had HIT. If we exclude these
patients, the incidence of HIT could be as low as 0Æ6%.
However, this result was compatible with our previous
retrospective study of the same patient population (the
incident of HIT was 0Æ5%) (Kawano et al, 2008). Therefore,
we can conclude that the incidence of HIT in acute stroke
patients treated with UFH seems to be approximately
0Æ5–1Æ7%. These results emphasize that HIT diagnosis should
be considered in the management of acute ischaemic stroke.
Another major ﬁnding was that the clinical severity and
outcome of acute stroke patients who were diagnosed as having
deﬁnite HIT were unfavourable. In particular, the in-hospital
mortality of deﬁnite HIT was very high (66Æ7%). Previous
reports also indicated that mortality was high in HIT patients
(Warkentin et al, 1995, 2000; Kappers-Klunne et al, 1997). The
present study is unique in that initial neurological severity and
clinical outcomes of stroke patients with HIT were determined.
The NIHSS score on admission (median, 17) in deﬁnite HIT
was quite high, and the outcome at 90 d was poor. However,
the poor outcome of those patients appeared to be mainly due
to the severity of the initial stroke rather than HIT. Although
clinical severity and outcome of patients treated with UFH were
unfavourable compared to those without UFH, the patients
with UFH intrinsically might be at high risk of thromboembolic
complications because those patients more frequently had
systemic atherosclerotic changes or embolic sources. In fact,
stroke subtypes were distributed differently between patients
with and without UFH in our study. Hoh et al (2005) reported
signiﬁcantly less favourable outcomes, including new throm-
boembolic episodes and deaths in patients with subarachnoid
haemorrhage who developed HIT compared to those without
HIT. They found that more patients with HIT showed a poorer
Fisher Grade than those without HIT, although the diagnosis of
HIT was based on clinical criteria, and serological examinations
were not mandatory in the study (Hoh et al, 2005). It should be
considered that serious neurological conditions might be
vulnerable to HIT.
In the present study, four of 165 clinical non-HIT patients
were positive by both ELISA and SRA. None of these patients
demonstrated thrombocytopenia, nor did they die. A throm-
boembolic event occurred in one patient who developed an
ischaemic heart event. Previous reports suggested that high OD
values in ELISA and/or strong-positive SRA results were
associated with a high degree of diagnostic accuracy for HIT
(Warkentin et al, 1995, 2008; Lo et al, 2007). However, despite
high OD values (‡1Æ5 units) in ELISA (Cases 8, 9, 11) or strong-
positive (‡50% serotonin release) SRA results (Cases 8, 9), these
patientsdidnotdevelopHIT(Table II).Oneoftheclinicalnon-
HIT patients was ELISA-negative but SRA-positive and did not
Fig 2. The correlation of optical density (OD) values for anti-platelet
factor 4/heparin antibodies detected by enzyme-linked immunosorbent
assay (ELISA) and mean percentage release by serotonin-release assay
(SRA). These values showed poor correlation. Arrows indicate the data
points ofthethreepatients who met the criteria for deﬁnite HIT. •,S R A -
positivecases,includingonepatientclassedas‘HITunlikely’:OD = 0Æ298,
and mean percentage release = 76Æ74; 4, SRA-negative cases.
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death. Furthermore, three of 95 patients without UFH were
positive only by ELISA. In the present study, we blindly
evaluated anti-PF4/heparin Abs in all clinical HIT and clinical
non-HIT patients. Even if the results of anti-PF4/heparin Abs
were positive, all patients with positive results would not always
demonstrate HIT, and some of the positive results might not be
pathological ﬁndings. Therefore, we should be aware of false
negative and false positive results in both serological tests, and
that diagnosis by the detection of anti-PF4/heparin Abs alone
(even with a high OD value in ELISA and/or a strong-positive
SRA result) can result in an overdiagnosis of HIT.
This study had some limitations. First, none of the patients
underwent venous ultrasound; therefore, subclinical DVT,
which is the typical thrombotic complication associated with
HIT, may have been underdiagnosed. Second, the dose of UFH
could be a determinant for the occurrence of HIT, as
stoichiometrically optimal ratios of PF4:heparin inﬂuence
immunization (Greinacher et al, 2008; Warkentin et al,
2010). However, in the present study, the dose and blood
levels of UFH were not investigated.
In conclusion, the incidence of deﬁnite HIT in acute
ischaemic stroke patients treated with UFH was 1Æ7% (95% CI:
0Æ4–5Æ0). HIT should be recognized as a clinicopathological
syndrome in which both the clinical proﬁle consistent with
HIT and the results of serological tests should be carefully
considered for HIT diagnosis. The clinical severity and
outcome of acute stroke patients who were diagnosed as
having deﬁnite HIT were unfavourable.
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